Posted : 23 Aug 2024
DengiAll-Phase-III-Vaccine Trial at ICMR-NIRBI: Call for participation

ICMR- National Institute for Research in Bacterial Infections (ICMR-NIRBI), a premier research organization, under the Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, is going to initiate a Drug Controller General of India (DCGI) approved trial titled “A Phase III, Multicenter, Randomized, Double- Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophilized)- “DengiAll” of Panacea Biotic Limited in Healthy Indian Adults.” The
objectives of the study are to evaluate the efficacy against Dengue fever and to determine the safety and Immunogenicity of the dengue vaccine - “DengiAll” in healthy adults. Participants of any gender of aged between 18-60 years, residing in Kolkata (preferably within 10 kms. of ICMR-NIRBI) are encouraged to participate voluntarily in this trial. Willing participants are requested to contact in this number (9903824322) or email ( DengiAllnirbi@gmail.com ) their personal details (name, age,sex, address, contact number, email, and comorbidities, if any) for further information. A limited number of participants will be enrolled in the study and they will be screened for eligibility criteria before enrolment in the study. The participant enrolment will continue till the target is achieved. View Details

Posted : 01 Sep 2023
IPV-01- Vaccine Trial at ICMR-NICED: Request for participation

ICMR-NICED, a premier research organisation, under the Dept. of Health Research, Ministry of Health and Family Welfare, Govt. of India, is going to initiate a CDSCO approved regulatory trial entitled "A Phase II/III, Multicenter, Double-Blind, Randomized, Active Controlled Study to evaluate Safety and Immunogenicity of SII Inactivated Salk Polio Vaccine (Adsorbed) in comparison with SII (Serum Institute of India) Licensed Inactivated Poliovirus Vaccine (IPV)". The Phase-III component of the study will be conducted under supervision of Dr. Shanta Dutta(Director & Scientist -G,ICMR-NICED). Mass vaccination with oral poliovirus vaccine (OPV) led to a reduction in the number of Wild type polio but there is a risk of the emergence of circulating vaccine-derived polioviruses in the environment as OPV uses live poliovirus. Global Polio Eradication Initiative (GPEI) recommended to gradually phase out Oral Polio Vaccine(OPV) and replace it with IPV to eliminate the risk of vaccine-derived polioviruses The primary objective of the proposed study is to evaluate the safety and immunogenicity of SII (Serum Institute of India) Inactivated Salk Polio Vaccine (Adsorbed).
Three doses of either SII Inactivated Salk Polio Vaccine (Adsorbed) or SII licensed IPV will be administered at 4 weeks apart with the first administration given at 6- 8 weeks of age. Parents of age eligible (6-8 weeks) potential participants of any gender residing in Kolkata (within 10 kms. of ICMR-NICED) are encouraged to participate with their child voluntarily in this trial.
Willing parents are requested to contact Dr.Suman Kanungo in this number (9903824322) or email (IPV01niced@gmail.com) with their personal details (name, age, sex, address, contact number, email and DOB of the child) for further information. Limited number of participants will be enrolled in the study and they will be screened for eligibility criteria before enrolment in the study. The participant enrolment will continue till the target is achieved. View Details

Posted : 26 Nov 2020
COVAXIN Phase III Trial : Request for participation

In pursuance to the letter from ICMR Hqrs. No.VIR/COVID-19/39/2020/ECD-1 dated 29/10/2020, it is to be informed that ICMR-NICED has been selected as one of the sites for conducting CDSCO approved regulatory trial entitled "An Event-driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter study to evaluate the efficacy, safety, immunogenicity and Lot-to-Lot consistency of BBV 152, a Whole-virion inactivated SARS-CoV-2 vaccine in adults ≥18 years of age". The trial will be carried out among volunteers to evaluate the efficacy of inactivated SARS-CoV2 vaccine against COVID-19 infection in adults more than 18 years of age to prevent symptomatic COVID-19. Participants residing in Kolkata (preferably within 10 KM of ICMR-NICED, Beliaghata) are encouraged to become the volunteers in this trial. Those who are willing to participate in this trial are instructed to send their requests over the number +919836169622 or email at bbv152niced@gmail.com  with their personal details (name, age, sex, address, contact number, email and comorbidities, if any) for consideration. As per trial protocol, limited number of participants will be enrolled in this trial after screening for their eligibility criteria. The eligible participants will be contacted for further details over the given Mobile/Email. Participants enrollment will continue until the target number is achieved.
- DIRECTOR

Dated: 02 April 2020

INFORMATION REGARDING TESTING OF SAMPLES FOR SARS-CoV-2 IN THE EMERGENCY SITUATION

• Regional VRDL, ICMR-NICED is a designated centre for testing of COVID-19, presently catering to the states of Sikkim and West Bengal.
• The Govt. approved testing centres of West Bengal and their district-wise linkage are mentioned in Annexure I.
• The properly collected, labelled and packaged clinical samples SHOULD BE SENT ONLY AFTER DUE INTIMATION TO THE NODAL PERSONS OF THE CORRESPONDING STATE HEALTH DEPARTMENTS (for WB refer Annexure I, www.wbhealth.gov.in  ).
• The strategy of COVID-19 testing in India laid by DHR/ICMR/MoH&FW and updated from time to time should be followed for selection of cases.
• Each sample should be accompanied by properly filled in Specimen Referral Form (Annexure II)
• Guidelines regarding sample collection, packaging and transport (Annexure III).
• Nodal Persons at Regional VRDL, ICMR-NICED (for any query regarding testing only):
  Dr. Ananya Chatterjee, 9933135866
  Dr. Agniva Majumdar, 9433756755

INFORMATION REGARDING TESTING OF SAMPLES FOR SARS-CoV-2 IN THE EMERGENCY SITUATION

Posted : 02 Apr 2020

View COVID-19 Guidelines: Information Regarding Testing of Samples for SARS-CoV-2 in the Emergency Situation

INFORMATION REGARDING TESTING OF SAMPLES FOR NOVEL CORONA VIRUS SARS-CoV-2a

Posted : 11 Mar 2020

 View  COVID Guidelines...

Rotavirus Vaccine Interchangeability Trial Begins Enrolling Participants in Kolkata, India

Posted : 24 Mar 2019

Rotavirus Vaccine Interchangeability Trial Begins Enrolling Participants in Kolkata, India

Diarrhoeal disease is one of the most important causes of illness and death among under five years children and Rotavirus is the most common agent causing acute watery diarrhoea in that age group. Rotavirus diarrhoea poses a major public health challenge, especially due to the dehydration caused by acute diarrhoea and vomiting, delayed health seeking behaviours of the caregivers of affected children, and lack of primary healthcare facilities in the vicinity of community settings. View Details...

14th ASCODD conference

Posted : 10 Aug 2017

14th ASCODD conference will be held during 30th October 2017 - 1st November 2017 at Kochi. Scientists and students interested to participate in the conference please check the link given here under http://www.ascodd.net/ 

Notices

Notice regarding Merit Based Assessment Promotion Scheme (MBAPS). Dated 19 Sep 2016
View Notice

NICED Microbiology and Serology laboratory received accreditation in the field of MEDICAL TESTING under 'National Accreditation Board for Testing and Calibration Laboratories (NABL)' ; ISO 15189:2012; Medical laboratories-Requirements for quality and competence.
Please click for 'Scope of accreditation'.